Replies to post #81558 on Biotech Values

[masterlongevity]

would love to see another MS market share table. here is some of the requisite info from Teva's release.

The company said its global market share for Copaxone was 28 percent, ahead of Biogen's (BIIB.O) Avonex, which was 24 percent and 21 percent for Merck KGaA's (MRCG.DE) Rebif.
It had a 38 percent market share in the United States.

Do you think tysabri has gotten out of the single digits? It was last reported as having 9% market share in the US, but the market has grown.